204 related articles for article (PubMed ID: 32352653)
1. Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies.
Deodhar AA; Miceli-Richard C; Baraliakos X; Marzo-Ortega H; Gladman DD; Blanco R; Das Gupta A; Martin R; Safi J; Porter B; Shete A; Rosenbaum JT
ACR Open Rheumatol; 2020 May; 2(5):294-299. PubMed ID: 32352653
[TBL] [Abstract][Full Text] [Related]
2. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
Elewski BE; Baddley JW; Deodhar AA; Magrey M; Rich PA; Soriano ER; Soung J; Bao W; Keininger D; Marfo K; Patekar M; Sharma A; Shete A; Lebwohl MG
JAMA Dermatol; 2021 Jan; 157(1):43-51. PubMed ID: 33001147
[TBL] [Abstract][Full Text] [Related]
3. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up.
Lebwohl M; Deodhar A; Griffiths CEM; Menter MA; Poddubnyy D; Bao W; Jehl V; Marfo K; Primatesta P; Shete A; Trivedi V; Mease PJ
Br J Dermatol; 2021 Nov; 185(5):935-944. PubMed ID: 33829482
[TBL] [Abstract][Full Text] [Related]
4. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
Schreiber S; Colombel JF; Feagan BG; Reich K; Deodhar AA; McInnes IB; Porter B; Das Gupta A; Pricop L; Fox T
Ann Rheum Dis; 2019 Apr; 78(4):473-479. PubMed ID: 30674475
[TBL] [Abstract][Full Text] [Related]
5. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Baeten D; Sieper J; Braun J; Baraliakos X; Dougados M; Emery P; Deodhar A; Porter B; Martin R; Andersson M; Mpofu S; Richards HB; ;
N Engl J Med; 2015 Dec; 373(26):2534-48. PubMed ID: 26699169
[TBL] [Abstract][Full Text] [Related]
6. Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies.
Schett G; Baraliakos X; Van den Bosch F; Deodhar A; Østergaard M; Gupta AD; Mpofu S; Fox T; Winseck A; Porter B; Shete A; Gensler LS
J Rheumatol; 2021 Aug; 48(8):1251-1258. PubMed ID: 33722947
[TBL] [Abstract][Full Text] [Related]
7. Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.
Deodhar A; Gladman DD; McInnes IB; Spindeldreher S; Martin R; Pricop L; Porter B; Safi J; Shete A; Bruin G
J Rheumatol; 2020 Apr; 47(4):539-547. PubMed ID: 31203228
[TBL] [Abstract][Full Text] [Related]
8. Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Gottlieb AB; Deodhar A; Mcinnes IB; Baraliakos X; Reich K; Schreiber S; Bao W; Marfo K; Richards HB; Pricop L; Shete A; Trivedi V; Keefe D; Papavassilis CC; Jagiello P; Papanastasiou P; Mease PJ; Lebwohl M
Acta Derm Venereol; 2022 Apr; 102():adv00698. PubMed ID: 35146532
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
Pavelka K; Kivitz A; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Pricop L; Andersson M; Readie A; Porter B
Arthritis Res Ther; 2017 Dec; 19(1):285. PubMed ID: 29273067
[TBL] [Abstract][Full Text] [Related]
10. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.
Braun J; Baraliakos X; Deodhar A; Baeten D; Sieper J; Emery P; Readie A; Martin R; Mpofu S; Richards HB;
Ann Rheum Dis; 2017 Jun; 76(6):1070-1077. PubMed ID: 27965257
[TBL] [Abstract][Full Text] [Related]
11. New-Onset Uveitis Possibly Caused by Secukinumab in a 47-Year-Old Male Patient with Long-Standing Ankylosing Spondylitis.
Nadwi H; Janaini M; Zammo M; Cheikh M; Almoallim H
Int Med Case Rep J; 2020; 13():331-334. PubMed ID: 32801946
[TBL] [Abstract][Full Text] [Related]
12. A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis.
van der Horst-Bruinsma I; Miceli-Richard C; Braun J; Marzo-Ortega H; Pavelka K; Kivitz AJ; Deodhar A; Bao W; Porter B; Pournara E
Rheumatol Ther; 2021 Dec; 8(4):1775-1787. PubMed ID: 34618347
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison.
Maksymowych WP; Strand V; Nash P; Yazici Y; Thom H; Hunger M; Kalyvas C; Gandhi KK; Porter B; Jugl SM
Eur J Rheumatol; 2018 Dec; 5(4):216-223. PubMed ID: 30388073
[TBL] [Abstract][Full Text] [Related]
14. Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies.
Braun J; Deodhar A; Landewé R; Baraliakos X; Miceli-Richard C; Sieper J; Quebe-Fehling E; Martin R; Porter B; Gandhi KK; van der Heijde D;
RMD Open; 2018; 4(2):e000749. PubMed ID: 30564451
[TBL] [Abstract][Full Text] [Related]
15. Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.
Marzo-Ortega H; Sieper J; Kivitz A; Blanco R; Cohen M; Martin R; Readie A; Richards HB; Porter B;
Arthritis Care Res (Hoboken); 2017 Jul; 69(7):1020-1029. PubMed ID: 28235249
[TBL] [Abstract][Full Text] [Related]
16. Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications.
Merola JF; McInnes IB; Deodhar AA; Dey AK; Adamstein NH; Quebe-Fehling E; Aassi M; Peine M; Mehta NN
Rheumatol Ther; 2022 Jun; 9(3):935-955. PubMed ID: 35305260
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L;
Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593
[TBL] [Abstract][Full Text] [Related]
18. Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab.
Kiltz U; Sfikakis PP; Gaffney K; Bounas A; Gullick N; Lespessailles E; Brandt-Juergens J; Rashkov R; Schulz B; Pournara E; Jagiello P
Rheumatol Ther; 2022 Aug; 9(4):1129-1142. PubMed ID: 35674938
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study.
Baraliakos X; Braun J; Deodhar A; Poddubnyy D; Kivitz A; Tahir H; Van den Bosch F; Delicha EM; Talloczy Z; Fierlinger A
RMD Open; 2019; 5(2):e001005. PubMed ID: 31565244
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.
Braun J; Baraliakos X; Deodhar A; Poddubnyy D; Emery P; Delicha EM; Talloczy Z; Porter B
Rheumatology (Oxford); 2019 May; 58(5):859-868. PubMed ID: 30590813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
